FDA Has Rejected Covaxin's Emergency Use In America; Here's Why
Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics license application (BLA) for Covaxin.
Stay updated with breaking news from Master File. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics license application (BLA) for Covaxin.
Indian students in the US who got themselves vaccinated with Covaxin or Sputnik V have been asked to get themselves re-vaccinated citing lack of WHO approval
TOKYO--(BUSINESS WIRE)--Mitsubishi Engineering-Plastics Corporation (MEP), a world leader in high-performance polyacetal materials, has developed a new polyacetal resin (POM), the Iupital MA Series, that is compliant with medical standards.The MA series is available in a range of standard, high-flow, high-rigidity,...
Ocugen Inc (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, has submitted a “Master ...
Ocugen submits ‘Master File’ to FDA on Covid vaccine Covaxin PTI Hyderabad | Updated on Bharat Biotech’s US partner is targeting 100 million doses per annum beginning 2021 Ocugen, Bharat Biotech’’s American partner for Covid-19 vaccine Covaxin, has submitted a “Master File” to the US Food and Drug Administration prior to seeking an emergency use authorisation in that country. “The company is currently evaluating the clinical and regulatory path for Covaxin in the US, including obtaining Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA). Also, e...